Broom Colin MD 4
4 · Nabriva Therapeutics plc · Filed Feb 2, 2018
Insider Transaction Report
Form 4
Broom Colin MD
Chief Executive Officer
Transactions
- Award
Stock Options
2018-01-31+200,000→ 200,000 totalExp: 2028-01-31→ Ordinary Shares (200,000 underlying) - Award
Restricted Stock Units
2018-01-31+67,500→ 67,500 totalExp: 2021-01-31→ Ordinary Shares (67,500 underlying)
Footnotes (4)
- [F1]The exercise price is $6.47 per share.
- [F2]The option award was granted on January 31, 2018. Vesting began on January 31, 2018 and ends on January 31, 2022. Twenty-five percent (25%) of the option award will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
- [F3]The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units.
- [F4]Vesting of the restricted stock unit award is subject to U.S. Food and Drug Administration ("FDA") approval of a new drug application ("NDA") for lefamulin. Fifty percent (50%) of the restricted stock unit award will vest upon FDA approval of an NDA for lefamulin, and the remaining fifty percent (50%) of the restricted stock unit award will vest on the one (1) year anniversary of such approval. If the FDA does not approve an NDA for lefamulin within two years of the grant date, the the restricted stock unit award will terminate in full.